glp-1 cardiovascular outcome trials Cardiovascular, mortality, and kidney outcomes with receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised GLP-1 Receptor Agonists for the

Seanna Grob, MD, MAS, FACS Clinical Associate Professor of Ophthalmology and Visual Sciences at the University of California, Irvine

SYSTEMIC LUPUS ERYTHEMATOSUS AND GLP-1RAS Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by systemic inflammation and multi-organ involvement

The short answer is that no clinically significant interaction has been identified in major drug interaction databases or FDA labeling

Their anti-inflammatory effects may theoretically provide mild benefit, though this has not been confirmed in clinical trials focused on Hashimoto's specifically

Diabetes 54 , 10561063 (2005)